France vs Peru: HIV/AIDS deaths averted by antiretroviral therapy
France
5,635 deaths
in 2022
Peru
6,549 deaths
in 2024
France rank
32nd
Peru rank
30th
HIV/AIDS deaths averted by antiretroviral therapy over time
- France
- Peru
How they compare
Peru currently reports 6,549 deaths against 5,635 deaths in France, a difference of 914 deaths.
That makes Peru's figure about 1.2 times France's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Peru ahead.
France ranks 32nd and Peru ranks 30th of 157 countries.
Across the 4 decades both report, France averaged higher in 3 and Peru in 1.
Head to head by decade
| Decade | France | Peru | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 869.7 deaths | 0 deaths | 869.7 deaths | France |
| 2000s | 5,347 deaths | 908.88 deaths | 4,438 deaths | France |
| 2010s | 6,037 deaths | 4,028 deaths | 2,009 deaths | France |
| 2020s | 5,744 deaths | 5,779 deaths | 35.39 deaths | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, France or Peru?
- Peru, at 6,549 deaths against 5,635 deaths in France as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between France and Peru?
- 914 deaths, with Peru ahead.
- How many years of comparable data are there for France and Peru?
- 33 years are reported by both, from 1990 to 2022.
- How do France and Peru rank globally for hiv/aids deaths averted by antiretroviral therapy?
- France ranks 32nd and Peru ranks 30th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.